BioCentury
ARTICLE | Clinical News

ENMD-2076: Phase I ongoing

May 19, 2008 7:00 AM UTC

EntreMed began dosing patients in a dose-escalation, U.S. Phase I trial of oral ENMD-2076. The initiation of dosing triggered a $2 million milestone payment, paid in EntreMed stock to the former share...